



## iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development

- Lead program IMT-07 addressing a novel immune checkpoint target in solid tumors will enter clinical development in late 2022

**Martinsried / Munich, Germany, 03 February, 2022** - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Dr. Murray Yule, M.D., Ph.D., as Chief Medical Officer (CMO), as of early January, 2022. Murray is a board-certified medical oncologist with extensive experience in leading clinical development programs. He has worked in the global pharmaceutical industry for over 20 years, planning and delivering clinical trials across the EU, US and Asia.

"This is an exciting time to work with iOmx and to implement the company's clinical strategies for its first-in-class cancer immunotherapy programs IMT-07, a small molecule SIK3 inhibitor, and IMT-18, an IGSF11-targeting antibody," said **Dr. Murray Yule, Chief Medical Officer with iOmx**. "I am delighted to join the outstanding team at iOmx at this important juncture and contribute to their successful transformation into a clinical stage organization. iOmx' approach to discover and target novel immune evasion biology is highly attractive to address the current gaps in cancer immunotherapy for patients in need. Our lead program, IMT-07, is currently proceeding with Clinical Trial Application (CTA)-enabling studies and aims to enter clinical development in late 2022."

"Today, the majority of cancers remain resistant to current immunotherapies, with only a relatively small number of patients benefiting from these treatment options. Based on our research, we see that our next-generation immune checkpoint programs have the potential for single-agent efficacy in multiple solid tumors that are resistant to current therapies," said **Dr. Apollon Papadimitriou, CEO of iOmx**. "It gives us great confidence to have the support of Dr. Yule, an experienced clinical oncologist and scientist. We are all looking forward to working with Murray to rapidly advance IMT-07 into the clinic and accelerate our other preclinical programs."

Dr. Yule is a board-certified medical oncologist who trained in the United Kingdom and also at the MD Anderson Cancer Centre in Houston, Texas. Whilst working at Eisai he played a pivotal role in the successful development and approval of Eribulin for the treatment of advanced breast cancer and liposarcoma. Immediately prior to joining iOmx he worked on the FDA approval of Tafasitamab for the treatment of non-Hodgkin Lymphoma at MorphoSys. Dr. Yule has been a member of the



Scientific Boards of Adcendo and Almac Discovery and has deep experience across a wide range of therapeutic approaches in the treatment of cancer ranging from small molecules to cellular therapy. He has extensive experience in partnering within the pharma industry and successfully listed Xynomic on the Nasdaq exchange.

### **About iOmx Therapeutics**

iOmx Therapeutics ([www.iomx.com](http://www.iomx.com)) is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company's lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors; the IMT-18 program is a first-in-class antibody designed to inhibit IGSF11, an immune checkpoint in PD-1/PD-L1-resistant tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Biopharma. iOmx is based in Martinsried/Munich, Germany.

### **Contact**

MC Services AG

Katja Arnold, Julia von Hummel, Shaun Brown

T: +49(0)89 2102280

[iomx@mc-services.eu](mailto:iomx@mc-services.eu)